{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:46:29Z","timestamp":1772135189795,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>By the end of July 2021, the majority of the Icelandic population had received vaccination against COVID-19. In mid-July a wave of SARS-CoV-2 infections, dominated by the Delta variant, spread through the population, followed by an Omicron wave in December. A booster vaccination campaign was initiated to curb the spread of the virus. We estimate the risk of infection for different vaccine combinations using vaccination data from 276,028 persons and 963,557 qPCR tests for 277,687 persons. We measure anti-Spike-RBD antibody levels and ACE2-Spike binding inhibitory activity in 371 persons who received one of four recommended vaccination schedules with or without an mRNA vaccine booster. Overall, we find different antibody levels and inhibitory activity in recommended vaccination schedules, reflected in the observed risk of SARS-CoV-2 infections. We observe an increased protection following mRNA boosters, against both Omicron and Delta variant infections, although BNT162b2 boosters provide greater protection against Omicron than mRNA-1273 boosters.<\/jats:p>","DOI":"10.1038\/s41467-022-33076-4","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T10:03:41Z","timestamp":1664359421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland"],"prefix":"10.1038","volume":"13","author":[{"given":"Gudmundur L.","family":"Norddahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pall","family":"Melsted","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristbjorg","family":"Gunnarsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-9862","authenticated-orcid":false,"given":"Gisli H.","family":"Halldorsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-938X","authenticated-orcid":false,"given":"Thorunn A.","family":"Olafsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaldur","family":"Gylfason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Kristjansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olafur T.","family":"Magnusson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7123-6123","authenticated-orcid":false,"given":"Patrick","family":"Sulem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5222-9857","authenticated-orcid":false,"given":"Daniel F.","family":"Gudbjartsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Unnur","family":"Thorsteinsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8339-150X","authenticated-orcid":false,"given":"Ingileif","family":"Jonsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1676-864X","authenticated-orcid":false,"given":"Kari","family":"Stefansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"33076_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5694\/mja2.51182","volume":"215","author":"DA Henry","year":"2021","unstructured":"Henry, D. A., Jones, M. A., Stehlik, P. & Glasziou, P. P. Effectiveness of COVID-19 vaccines: findings from real world studies. Med. J. Aust. 215, 149\u2013151.e1 (2021).","journal-title":"Med. J. Aust."},{"key":"33076_CR2","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","volume":"373","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 373, n1088 (2021).","journal-title":"BMJ"},{"key":"33076_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u201315. (2020).","journal-title":"N. Engl. J. Med"},{"key":"33076_CR4","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1093\/cid\/ciab079","volume":"73","author":"SM Moghadas","year":"2021","unstructured":"Moghadas, S. M. et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clin. Infect. Dis. 73, 2257\u201364. (2021).","journal-title":"Clin. Infect. Dis."},{"key":"33076_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116597","author":"DW Eyre","year":"2022","unstructured":"Eyre, D. W. et al. Effect of Covid-19 vaccination on transmission of alpha and delta variants. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2116597 (2022).","journal-title":"N. Engl. J. Med."},{"key":"33076_CR6","unstructured":"Directorate of Health Iceland. Continued use of Astra Zeneca COVID-19 vaccine (Vaxzevria) in Iceland. https:\/\/www.landlaeknir.is\/english\/news\/detail\/item45021\/continued-use-of-astra-zeneca-covid-19-vaccine-vaxzevria-in-iceland (2021) (accessed 11 Jan 2022)."},{"key":"33076_CR7","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On, Y. M. et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 385, 1393\u2013400. (2021).","journal-title":"N. Engl. J. Med."},{"key":"33076_CR8","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1056\/NEJMoa2115926","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On, Y. M. et al. Protection against Covid-19 by BNT162b2 booster across age groups. N. Engl. J. Med. 385, 2421\u201330. (2021).","journal-title":"N. Engl. J. Med."},{"key":"33076_CR9","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2115624","volume":"385","author":"R Arbel","year":"2021","unstructured":"Arbel, R. et al. BNT162b2 vaccine booster and mortality due to Covid-19. N. Engl. J. Med. 385, 2413\u201320. (2021).","journal-title":"N. Engl. J. Med."},{"key":"33076_CR10","unstructured":"Directorate of Health Iceland. Booster vaccinations for COVID-19. https:\/\/www.landlaeknir.is\/um-embaettid\/greinar\/grein\/item47311\/booster-vaccinations-for-covid-19- (accessed 14 Jan 2022)."},{"key":"33076_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116747","author":"RSG Sablerolles","year":"2022","unstructured":"Sablerolles, R. S. G. et al. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2116747 (2022).","journal-title":"N. Engl. J. Med."},{"key":"33076_CR12","unstructured":"Directorate of Health Iceland. The Chief Epidemiologist recommends a third dose for everyone 16 years and older when 6 months have passed since their primary vaccination against COVID-19. https:\/\/www.landlaeknir.is\/um-embaettid\/frettir\/frett\/item48038\/The-Chief-Epidemiologist-recommends-a-third-dose-for-everyone-16-years-and-older-when-6-months-have-passed-since-their-primary-vaccination-against-COVID-19 (accessed 14 Jan 2022)."},{"key":"33076_CR13","unstructured":"Directorate of Health Iceland. Uppl\u00fdsingar um ra\u00f0greiningu \u00e1 SARS-CoV-2 veiru. https:\/\/www.landlaeknir.is\/um-embaettid\/frettir\/frett\/item48456\/upplysingar-um-radgreiningu-a-sars-cov-2-veiru (accessed 14 Jan 2022)."},{"key":"33076_CR14","doi-asserted-by":"crossref","unstructured":"Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2119358 (2021).","DOI":"10.1101\/2021.12.13.21267670"},{"key":"33076_CR15","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 398, 2093\u2013100. (2021).","journal-title":"Lancet"},{"key":"33076_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMc2119270","volume":"386","author":"S Collie","year":"2021","unstructured":"Collie, S., Champion, J., Moultrie, H., Bekker, L.-G. & Gray, G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N. Engl. J. Med. 386, 494\u2013496 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33076_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","volume":"386","author":"F Schmidt","year":"2021","unstructured":"Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N. Engl. J. Med. 386, 599\u2013601 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33076_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","volume":"185","author":"WF Garcia-Beltran","year":"2022","unstructured":"Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457\u2013466.e4 (2022).","journal-title":"Cell"},{"key":"33076_CR19","unstructured":"The Directorate of Health and The Department of Civil Protection and Emergency Management Iceland. COVID-19 vaccinations in Iceland\u2014statistics. https:\/\/www.covid.is\/statistical-information-on-vaccination (accessed 14 Jan 2022)."},{"key":"33076_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","volume":"398","author":"M Shrotri","year":"2021","unstructured":"Shrotri, M. et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 398, 385\u2013387 (2021).","journal-title":"Lancet"},{"key":"33076_CR21","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33076_CR22","doi-asserted-by":"publisher","first-page":"6984","DOI":"10.1016\/j.vaccine.2021.10.038","volume":"39","author":"J Khoury","year":"2021","unstructured":"Khoury, J. et al. COVID-19 vaccine\u2014long term immune decline and breakthrough infections. Vaccine 39, 6984\u20136989 (2021).","journal-title":"Vaccine"},{"key":"33076_CR23","doi-asserted-by":"publisher","unstructured":"Nordstr\u00f6m, P, Ballin, M & Nordstr\u00f6m, A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet 0. https:\/\/doi.org\/10.1016\/S0140-6736(22)00089-7 (2022).","DOI":"10.1016\/S0140-6736(22)00089-7"},{"key":"33076_CR24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u201311. (2021).","journal-title":"Nat. Med"},{"key":"33076_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-021-04120-y","volume":"600","author":"B Pozzetto","year":"2021","unstructured":"Pozzetto, B. et al. Immunogenicity and efficacy of heterologous ChAdOx1\u2013BNT162b2 vaccination. Nature 600, 701\u2013706 (2021).","journal-title":"Nature"},{"key":"33076_CR26","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","volume":"27","author":"T Schmidt","year":"2021","unstructured":"Schmidt, T. et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination. Nat. Med. 27, 1530\u20131535 (2021).","journal-title":"Nat. Med"},{"key":"33076_CR27","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","volume":"27","author":"J Barros-Martins","year":"2021","unstructured":"Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination. Nat. Med. 27, 1525\u20131529 (2021).","journal-title":"Nat. Med"},{"key":"33076_CR28","doi-asserted-by":"publisher","first-page":"103410","DOI":"10.1016\/j.ebiom.2021.103410","volume":"68","author":"SS Nielsen","year":"2021","unstructured":"Nielsen, S. S. et al. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. EBioMedicine 68, 103410 (2021).","journal-title":"EBioMedicine"},{"key":"33076_CR29","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org\/ (2021)."},{"key":"33076_CR30","unstructured":"Therneau, TM. A Package for Survival Analysis in R. https:\/\/CRAN.R-project.org\/package=survival (2021)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33076-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33076-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33076-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T10:04:58Z","timestamp":1664359498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33076-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["33076"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-33076-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.26.22271509","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"26 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5701"}}